Compare Cytokinetics Inc (CYTK) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Kyndryl Holdings Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Kyndryl Holdings Inc trades at $13.26 (market cap $2.97B). The key difference: Cytokinetics Inc is far larger — about 3.6× Kyndryl Holdings Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | KD | |
|---|---|---|
Market Cap | $10.78B | $2.97B |
Sector | Technology | Technology |
52-Week High | $87.26 | $33.14 |
52-Week Low | $34.31 | $10.59 |
Enterprise Value | $10.88B | $5.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Kyndryl (KD) trades at $14.02, showing modest daily gains of 0.21%. The stock maintains a bullish technical signal with strong moving average support. Fundamentally, the company achieved profitability in 2025 with $252M net income after three years of losses, though revenue declined to $15.1B. Recent developments include the planned acquisition of Healthcare IT Leaders to boost AI capabilities and Q1 2027 results showing a $0.12 per share loss on $3.6B revenue.
While Kyndryl demonstrates improving profitability and strategic AI investments, investors face mixed signals with analyst consensus leaning hold (71%) and revenue declines. The stock trades near analyst targets with upside limited to technical momentum. Key risks include ongoing revenue pressure and the integration challenges of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
